Ovid Therapeutics - Jeremy LevinStatementLong version of The BIOSECURE Act: The Wes...By Jeremy Levin, D.Phil, MB BChir more ➔
Asabys PartnersFinancingAsabys Partners close €180m Sabadell Asa...Asabys Partners have announced the closing of a new oversubscribed fund aimed at investing in 12-15 companies across all areas of pharma biotech. more ➔
SR-TigitFinancingGenespire raises US$52m in Series B roundItalian SR-Tiget spin out Genespire srl will use the proceeds of a €46.6m (US$52m) Series B financing to advance its paediatric in-vivo gene therapy for the rare metabolic disorder Methylmalonic Acidemia … more ➔
Image by freepikAMRAMR Accelerator urges long-term fundingAntimicrobial resistance (AMR) poses a huge threat to the prevention and treatment of a growing number of infections caused by bacteria, parasites, viruses, and fungi. A public-private partnership involving … more ➔
CDC/Phil_ImagesVaccinesVicebio Ltd cashes in US$100m in Series B...London-based Vicebio Ltd has announced a US$100m Series B financing that will support Phase I testing of its bivalent RSV vaccine candidate VXB-241 and pushing development of another pipeline progra … more ➔
Brenus Pharma SAFinancingFrench Brenus AS closes US$25m financingFrench Brenus Pharma SA has raised €22.2m (US$25m) to accelerate clinical trials of two precision cancer vaccines derived from tumour cell banks representing more than 200 tumour antigens. more ➔
UE 2024 - PEEU Von der Leyen names new EU CommissionersEuropean Commission President Ursula von der Leyen has revealed her nominees for new commissioners to lead the bloc for the next term from 2024 to 2029. more ➔
ImmunOs Therapeutics AG FinancingImmunOs Therapeutics AG raises US$11m in S...Swiss cancer and auto-immunity specialist ImmunOs Therapeutics AG has closed a Series C financing round of US$11m led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners … more ➔
BIOCOM Interrelations GmbHContract biomanufacturingRichter-Helm Biologics triples production...After three and a half years of construction, the CDMO Richter Biologics has inaugurated its new multipurpose production facility that triples the CDMO’s capacity for the bacterial production of pDNA, … more ➔
Phoremost LtdProtein DegradersPhoremost reports Series B extensionBritish protein degrader specialist PhoreMost Ltd has extended its €33m Series B financing to $50M and plans to advance its oncology and inflammation degrader programmes. more ➔
Ovid Therapeutics - Jeremy Levin
Asabys Partners
SR-Tigit
Image by freepik
CDC/Phil_Images
Brenus Pharma SA
UE 2024 - PE
ImmunOs Therapeutics AG 
BIOCOM Interrelations GmbH
Phoremost Ltd